Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non‐ST segment elevation acute coronary …
X Bosch, J Marrugat, J Sanchis - Cochrane Database of …, 2013 - cochranelibrary.com
X Bosch, J Marrugat, J Sanchis
Cochrane Database of Systematic Reviews, 2013•cochranelibrary.comBackground During percutaneous coronary intervention (PCI), and in non‐ST segment
elevation acute coronary syndromes (NSTEACS), the risk of acute vessel occlusion by
thrombosis is high. Glycoprotein IIb/IIIa blockers strongly inhibit platelet aggregation and
may prevent mortality and myocardial infarction. This is an update of a Cochrane review first
published in 2001, and previously updated in 2007 and 2010. Objectives To assess the
efficacy and safety effects of glycoprotein IIb/IIIa blockers when administered during PCI, and …
elevation acute coronary syndromes (NSTEACS), the risk of acute vessel occlusion by
thrombosis is high. Glycoprotein IIb/IIIa blockers strongly inhibit platelet aggregation and
may prevent mortality and myocardial infarction. This is an update of a Cochrane review first
published in 2001, and previously updated in 2007 and 2010. Objectives To assess the
efficacy and safety effects of glycoprotein IIb/IIIa blockers when administered during PCI, and …
Abstract
Background
During percutaneous coronary intervention (PCI), and in non‐ST segment elevation acute coronary syndromes (NSTEACS), the risk of acute vessel occlusion by thrombosis is high. Glycoprotein IIb/IIIa blockers strongly inhibit platelet aggregation and may prevent mortality and myocardial infarction. This is an update of a Cochrane review first published in 2001, and previously updated in 2007 and 2010.
Objectives
To assess the efficacy and safety effects of glycoprotein IIb/IIIa blockers when administered during PCI, and as initial medical treatment in patients with NSTEACS.
cochranelibrary.com